Reacción a "'Science' magazine chooses lenacapavir to prevent HIV infection as breakthrough of the year"

Lenacapavir is the first of a new family of antiretrovirals that inhibit HIV capsid formation. It is a molecule that can be administered orally (daily or weekly) or parenterally subcutaneously every six months. A major study published in 2024 shows that subcutaneous administration of lenacapavir every six months prevents 100% of potential HIV infection. In the clinical development of lenacapavir, its use in prophylaxis and treatment of infected people (in combination with other antiretrovirals) is foreseen. Because of the impact this could have on controlling the HIV pandemic, it certainly deserves to be considered this year's most important medical breakthrough.